ES2389480T3 - Composiciones farmacéuticas para el tratamiento del asma - Google Patents

Composiciones farmacéuticas para el tratamiento del asma Download PDF

Info

Publication number
ES2389480T3
ES2389480T3 ES10012751T ES10012751T ES2389480T3 ES 2389480 T3 ES2389480 T3 ES 2389480T3 ES 10012751 T ES10012751 T ES 10012751T ES 10012751 T ES10012751 T ES 10012751T ES 2389480 T3 ES2389480 T3 ES 2389480T3
Authority
ES
Spain
Prior art keywords
mometasone furoate
formoterol fumarate
inhalation
dose inhaler
aerosol suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10012751T
Other languages
English (en)
Spanish (es)
Inventor
Joel A. Sequeira
Stefan A. Sharpe
John L. Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Schering Corp
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2389480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Schering Corp, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2389480T3 publication Critical patent/ES2389480T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES10012751T 2001-08-28 2002-08-27 Composiciones farmacéuticas para el tratamiento del asma Expired - Lifetime ES2389480T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
US315386P 2001-08-28

Publications (1)

Publication Number Publication Date
ES2389480T3 true ES2389480T3 (es) 2012-10-26

Family

ID=23224164

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10012751T Expired - Lifetime ES2389480T3 (es) 2001-08-28 2002-08-27 Composiciones farmacéuticas para el tratamiento del asma
ES09006110T Expired - Lifetime ES2361805T3 (es) 2001-08-28 2002-08-27 Composiciones farmacéuticas para el tratamiento del asma.
ES02753549T Expired - Lifetime ES2325316T3 (es) 2001-08-28 2002-08-27 Composiciones farmaceuticas para el tratamiento del asma.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES09006110T Expired - Lifetime ES2361805T3 (es) 2001-08-28 2002-08-27 Composiciones farmacéuticas para el tratamiento del asma.
ES02753549T Expired - Lifetime ES2325316T3 (es) 2001-08-28 2002-08-27 Composiciones farmaceuticas para el tratamiento del asma.

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP2319494B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN101856362A (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE430555T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK2092935T3 (enExample)
ES (3) ES2389480T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT2092935E (enExample)
SI (2) SI2092935T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング コーポレイション 薬学的組成物
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1711164B1 (en) * 2004-01-21 2010-03-24 Schering Corporation Method of treating acute rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
EP2117504A1 (en) * 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
MX2010007569A (es) * 2008-01-10 2011-03-21 Schering Corp Star Productos farmaceuticos para inhalacion, sistemas y usos.
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
AP3141A (en) 2009-11-25 2015-02-28 Boehringer Ingelheim Int Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
SG10201710156RA (en) * 2009-12-07 2018-01-30 Raptor Therapeutics Inc 4-methylpyrazole formulations
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
CN106456913B (zh) 2014-05-07 2019-08-30 勃林格殷格翰国际有限公司 喷雾器和容器
EP3139984B1 (en) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Nebulizer
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
ES2952510T3 (es) 2014-06-30 2023-10-31 Proveris Scient Corporation Aparato de muestreo para determinar la cantidad y uniformidad de una dosis administrada de medicamento y métodos relacionados
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CA3016890A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CZ294064B6 (cs) * 1996-08-29 2004-09-15 Schering Corporation Aerosolový suspenzní přípravek mometazonfuroátu bez chlorfluorovaných uhlovodíků
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
EP1133301A1 (en) * 1998-11-26 2001-09-19 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
ES2220724T3 (es) * 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Composiciones de peptidos ciclicos administrables por via nasal.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
TWI324934B (en) 2010-05-21
EP1420759B1 (en) 2009-05-06
DK2092935T3 (da) 2011-07-18
PE20030390A1 (es) 2003-04-24
CN1649568B (zh) 2010-10-27
SI1420759T1 (sl) 2009-10-31
EP1420759A2 (en) 2004-05-26
WO2003020253A3 (en) 2003-05-22
HUP0401514A3 (en) 2012-08-28
NO20041277L (no) 2004-03-26
CN101856362A (zh) 2010-10-13
CA2457926A1 (en) 2003-03-13
CN1649568A (zh) 2005-08-03
MXPA04001875A (es) 2004-06-15
KR100970531B1 (ko) 2010-07-16
NZ530987A (en) 2006-08-31
DK1420759T3 (da) 2009-08-03
CY1109212T1 (el) 2014-07-02
BR0212089A (pt) 2004-08-03
JP2009185075A (ja) 2009-08-20
CY1111726T1 (el) 2015-10-07
JP2010138184A (ja) 2010-06-24
AR036358A1 (es) 2004-09-01
EP2092935A1 (en) 2009-08-26
ZA200401419B (en) 2005-01-26
ATE430555T1 (de) 2009-05-15
US20050147565A1 (en) 2005-07-07
PT2092935E (pt) 2011-05-31
US20100143269A1 (en) 2010-06-10
HUP0401514A2 (hu) 2004-12-28
ATE503461T1 (de) 2011-04-15
ES2325316T3 (es) 2009-09-01
JP2005502675A (ja) 2005-01-27
KR20040031002A (ko) 2004-04-09
US20030114428A1 (en) 2003-06-19
DE60232251D1 (de) 2009-06-18
HK1128428A1 (en) 2009-10-30
EP2319494B1 (en) 2012-06-13
JP5170789B2 (ja) 2013-03-27
CO5560551A2 (es) 2005-09-30
ES2361805T3 (es) 2011-06-22
PL209640B1 (pl) 2011-09-30
HK1151987A1 (en) 2012-02-17
EP2092935B1 (en) 2011-03-30
AU2002313828B2 (en) 2005-09-08
PL368897A1 (en) 2005-04-04
PT1420759E (pt) 2009-06-30
SI2092935T1 (sl) 2011-07-29
EP2319494A1 (en) 2011-05-11
DE60239648D1 (de) 2011-05-12
HK1060972A1 (en) 2004-09-03
WO2003020253A2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
ES2389480T3 (es) Composiciones farmacéuticas para el tratamiento del asma
ES2234266T3 (es) Formulaciones medicas para aerosoles.
EP0656206B1 (en) Non-chlorofluorocarbon aerosol formulations
AU2002313828A1 (en) Pharmaceutical compositions for the treatment of asthma
ES2269582T3 (es) Formulaciones en aerosol sin clorofluorocarbonos.
US20080066744A1 (en) Process for producing metered dose inhaler formulations
US20100095963A1 (en) Pharmaceutical compositions
ES2568913T3 (es) Formulaciones farmacéuticas en aerosol de formoterol y dipropionato de beclometasona
US20110182830A1 (en) Inhalation drug products, systems and uses
HK1151987B (en) Pharmaceutical compositions for the treatment of asthma
HK1128428B (en) Pharmaceutical compositions for the treatment of asthma
HK1060972B (en) Pharmaceutical compositions for the treatment of asthma